OAM
KZR

Oxford Asset Management’s Kezar Life Sciences KZR Stock Holding History

Oxford Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,819
Closed -$92K – 1922
2019
Q3 		$92K Buy
+2,819
New +$136K ﹤0.01% 1636

Other funds holding KZR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oxford Asset Management's KZR Position: Q4 2019 in Review

Oxford Asset Management sold out of Kezar Life Sciences (KZR) in Q4 2019, closing a stake of 2,819 shares — an estimated $92K sold.

Oxford Asset Management first reported a position in KZR in Q3 2019 and held it in 1 quarter. The position peaked at $92K in Q3 2019. 55 funds tracked by Wall St. Rank hold KZR as of Q4 2019.

  • Oxford Asset Management reported no remaining Kezar Life Sciences position as of Q4 2019 after selling out during the quarter.
  • Oxford Asset Management sold 2,819 Kezar Life Sciences shares in Q4 2019, an estimated $92K.
  • Oxford Asset Management first reported a position in Kezar Life Sciences in Q3 2019 and held it in 1 quarter.
  • Oxford Asset Management's Kezar Life Sciences position peaked at $92K in Q3 2019.
  • 55 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.